Workflow
Beyond Air(XAIR)
icon
Search documents
Beyond Air(XAIR) - 2020 Q3 - Earnings Call Transcript
2020-02-10 18:05
Beyond Air, Inc. (NASDAQ:XAIR) Q3 2020 Results Conference Call February 7, 2020 11:00 AM ET Company Participants Monique Kosse - LifeSci Advisors Steve Lisi - Chairman and CEO Douglas Beck - Chief Financial Officer Amir Avniel - President and Chief Operating Officer Conference Call Participants Suraj Kalia - Oppenheimer Matt Kaplan - Ladenburg Thalmann Scott Henry - Roth Capital I-Eh Jen - Laidlaw Company Rahul Rakhit - LifeSci Capital James Molloy - Alliance Global Partners Operator Good morning, and welco ...
Beyond Air(XAIR) - 2020 Q3 - Quarterly Report
2020-02-07 22:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...
Beyond Air (XAIR) Investor Presentation - Slideshow
2019-11-07 20:48
Transforming the lives of patients with respiratory conditions Transformational Therapies to Treat Serious Lung Infections & Pulmonary Hypertension Corporate Presentation November 2019 Forward Looking Statement This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the "Company") nor shall there be any sale of securities in any jurisdiction in which such ...
Beyond Air(XAIR) - 2020 Q2 - Quarterly Report
2019-11-06 22:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...
Beyond Air (XAIR) Investor Presentation - Slideshow
2019-09-27 16:54
Transforming the lives of patients with respiratory conditions Transformational Therapies to Treat Serious Lung Infections & Pulmonary Hypertension Corporate Presentation September 2019 Forward Looking Statement This presentation is for confidential and informational purposes only. This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the "Company") nor shall there be any sale of securities i ...
Beyond Air(XAIR) - 2020 Q1 - Quarterly Report
2019-08-14 20:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 825 East Gate Boulevard, Suite 320 Garden City, NY 11530 (Address of principal executive offices) (Zip Code) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 000-55759 B ...
Beyond Air(XAIR) - 2019 Q4 - Annual Report
2019-06-27 22:48
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or Other Jurisdiction of Incorporation or Organization) 825 Ea ...
AIT Therapeutics (AITB) To Present At Oppenheimer 29th Annual Healthcare Conference - Slideshow
2019-03-21 16:26
AIT Therapeutics Overview - AIT Therapeutics is a medical device company developing a Nitric Oxide generator system for various respiratory conditions[16, 194] - The company's proprietary technology generates NO from ambient air, eliminating the need for cylinders and potentially enabling home use[16, 124, 194] - AIT's Nitric Oxide Delivery System has demonstrated a safety record at a concentration of 160 ppm NO, with over 2,100 treatments in over 85 patients across 7 studies and no Serious Adverse Events (SAEs) related to NO therapy[16, 91, 92, 194] Target Indications and Market Potential - Pulmonary Hypertension (in-hospital): US sales potential >$300 million, worldwide sales potential >$600 million, with a planned launch in 2020[16, 155, 194] - Bronchiolitis (in-hospital): US sales potential >$500 million, worldwide sales potential >$12 billion, with a planned launch in 2021[16, 96, 155, 194] - Severe Lung Infections (at-home): US sales potential >$1 billion, worldwide sales potential >$25 billion, with a planned launch in 2023, initially targeting NTM abscessus (MABSC)[16, 126, 148, 155, 194] AirNOvent Platform and Partnership - AirNOvent is AIT's cylinder-free Nitric Oxide therapeutic platform for pulmonary hypertension treatment in the hospital setting[45, 52] - AIT has a partnership with Circassia Pharmaceuticals, with potential milestones of $3255 million and royalties of 15-20% on gross profit[78, 88] - AIT anticipates PMA filing with the FDA in the Second Quarter of 2019 and US commercial launch planned for the First Half of 2020[88] Financial Status - As of February 1, 2019, AIT had $13 million in cash and $0 in debt, with an expected monthly burn rate of $600,000-$650,000[176]
Beyond Air(XAIR) - 2019 Q3 - Quarterly Report
2019-02-14 21:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 000-55759 AIT Therapeutics, Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ (State or other jurisdiction ...